Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS

Phase 2positivePositive

AI Analysis

Summary

Kailera Therapeutics and Hengrui Pharma's GLP-1/GIP candidate demonstrated positive Phase 2 results, achieving weight loss and improving menstrual cycle regularity in women with polyendocrine metabolic ovarian syndrome.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Weekly injection demonstrated weight loss benefits and improved menstrual cycle regularity in patients with PMOS

Importance:6/10

Sentiment:

0.75

GLP-1GIPweight lossPMOSmenstrual healthmid-stage trialweekly injection

Related Companies

$KLRA

Read the original article

Published by BioSpace on October 2, 2026 12:46 PM

Read Original